SCHEMBL248398

SCHEMBL248398

COc1cncc(-c2cnc(Cl)cc2N)c1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.37
GAA P10253 1/20 0.35
NPC1 O15118 1/20 0.35
HSP90AA1 P07900 3/20 0.33
HSP90AB1 P08238 3/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
G6PD P11413 1/20 0.33
PDE10A Q9Y233 1/20 0.32
FYN P06241 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ATR Q13535 2/20 0.31
P2RX3 P56373 1/20 0.31
P2RX2 Q9UBL9 1/20 0.31
DYRK1A Q13627 1/20 0.31
ACVR1 Q04771 2/20 0.30
ACVR1B P36896 1/20 0.30
TGFBR1 P36897 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL442333 0.77 HSP90AA1 (0.52) GAAHSP90AA1HSP90AB1ADORA2AADORA1
SCHEMBL247318 0.76 NNMT (0.37) DHFRGAANPC1FYNKDM4E
SCHEMBL16641778 0.75 GAA (0.50) DHFRGAANPC1HSP90AA1HSP90AB1
SCHEMBL248397 0.73 CYP11B1 (0.48)
SCHEMBL248167 0.72 PIK3CA (0.46) PDE10AFYNALDH1A1ATRACVR1
SCHEMBL14993864 0.71 GAA (0.50) DHFRGAANPC1HSP90AA1HSP90AB1
SCHEMBL29829655 0.71 GAA (0.50) DHFRGAANPC1HSP90AA1HSP90AB1
SCHEMBL21827702 0.70 ALDH1A1 (0.39) GAANPC1KDM4EALDH1A1P2RX3
SCHEMBL247109 0.70 ALDH1A1 (0.47) NPC1ADORA2AADORA1FYNALDH1A1
SCHEMBL2953394 0.68 ALDH1A1 (0.39) GAANPC1KDM4EALDH1A1P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 DHFR 3632/4885GAA 2673/4885NPC1 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.